1
Lymphomas
July 2014
This bulletin covers aspects of lymphomas and should be of interest to multidisciplinary teams working in
this area.
Sections can include:
 Combined Modality Therapies
 Drug & Biological Therapies
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Stem Cell Transplantation
 Supportive Care & Symptom Management
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of available
online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you would
like to request a print copy, please submit your request online at www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is not
intended to be comprehensive. Professional judgment should be exercised when appraising the material.
The Library takes no responsibility for the wording, content and accuracy of the information supplied,
which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the
content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
1
2
General
Ansell, S.M. (2014). Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and
management. American Journal of Hematology 89,7:771-779.
Bruno Ventre, M., Ferreri, A.J., Gospodarowicz, M., et al. (2014). Clinical features, management, and
prognosis of an international series of 161 patients with limited-stage diffuse large B-cell
lymphoma of the bone (the IELSG-14 study). Oncologist 19,3:291-298.
Freedman, A. (2014). Follicular lymphoma: 2014 update on diagnosis and management. American
Journal of Hematology 89,4:429-436.
Hentrich M. Hoffmann C. Mosthaf F. Muller M. Siehl J. Wyen C. Hensel M. German Study Group of
Physicians in Private Practice Treating HIV-Infected Patients (DAGNA). German AIDS Society (DAIG).
(2014). Therapy of HIV-associated lymphoma-recommendations of the oncology working group of
the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients
(DAGNA), in cooperation with the German AIDS Society (DAIG). Annals of Hematology 93,6:913-921.
Messina C. Ferreri AJ. Govi S. Bruno-Ventre M. Gracia Medina EA. Porter D. Radford J. Heo DS. Park
HY. Pro B. Jayamohan J. Visco C. Scarfo L. Zucca E. Gospodarowicz M. Christie D. International
Extranodal Lymphoma Study Group (I.E.L.S.G.). (2014). Clinical features, management and prognosis
of multifocal primary bone lymphoma: a retrospective study of the international extranodal
lymphoma study group (the IELSG 14 study). British journal of haematology 164,6:834-840.
Moskowitz, A.J., Lunning, M.A. and Horwitz, S.M. (2014). How I treat the peripheral T-cell lymphomas.
Blood 123,17:2636-2644.
Zaja, F., Federico, M., Vitolo, U., et al. (2014). Management of relapsed/refractory mantle cell
lymphoma: a review of current therapeutic strategies. Leukemia & lymphoma 55,5:988-998.
Zelenetz, A.D., Gordon, L.I., Wierda, W.G., et al. (2014). Non-Hodgkin's Lymphomas, Version 2.2014.
Journal of the National Comprehensive Cancer Network 12,6:916-946.
Combined Modality Therapies
Bersvendsen, H., Kolstad, A., Blystad, A.K., et al. (2014). Multimodal treatment with ALL-like
chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma. Acta Oncologica 53,5:680687.
Briones J. Novelli S. Garcia-Marco JA. Tomas JF. Bernal T. Grande C. Canales MA. Torres A. Moraleda
JM. Panizo C. Jarque I. Palmero F. Hernandez M. Gonzalez-Barca E. Lopez D. Caballero D. Grupo
Espanol de Linfomas y Trasplante Autologo de Medula Osea (GELTAMO). (2014). Autologous stem
cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory
non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical
trial. Haematologica 99,7:e126.
Glass, B., Hasenkamp, J., Wulf, G., et al. (2014). Rituximab after lymphoma-directed conditioning
and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin
lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncology 15,7:757-766.
2
3
Jiang, L., Li, S.J., Jiang, Y.M., et al. (2014). The significance of combining radiotherapy with
chemotherapy for early stage extranodal natural killer/T-cell lymphoma, nasal type: a systematic
review and meta-analysis. Leukemia & lymphoma 55,5:1038-1048.
Metzner, B., Muller, T.H., Gebauer, W., et al. (2014). Long-term clinical and molecular remissions in
patients with mantle cell lymphoma following high-dose therapy and autologous stem cell
transplantation. Annals of Hematology 93,5:803-810.
Waibel, M., Gregory, G., Shortt, J., et al. (2014). Rational combination therapies targeting survival
signaling in aggressive B-cell leukemia/lymphoma. Current opinion in hematology 21,4:297-308.
Drug & Biological Therapies
Advani, A.S., McDonough, S., Coutre, S., et al. (2014). SWOG S0910: a phase 2 trial of
clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. British
journal of haematology 165,4:504-509.
Chang, J.E., Li, H., Smith, M.R., et al. (2014). Phase 2 study of VcR-CVAD with maintenance
rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study
(E1405). Blood 123,11:1665-1673.
de Vos, S., Forero-Torres, A., Ansell, S.M., et al. (2014). A phase II study of dacetuzumab (SGN-40) in
patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patientspecific factors. Journal of hematology & oncology 7,1:44.
Derenzini, E., Zinzani, P.L. and Cheson, B.D. (2014). Bendamustine: role and evidence in lymphoma
therapy, an overview. Leukemia & lymphoma 55,7:1471-1478.
Desai, M., Newberry, K., Ou, Z., et al. (2014). Lenalidomide in relapsed or refractory mantle cell
lymphoma: overview and perspective. Therapeutic Advances in Hematology 5,3:91-101.
Dickinson, M. and Prince, H.M. (2014). Emerging drugs for T-cell lymphoma. Expert Opinion on
Emerging Drugs 19,2:201-213.
Eichenauer, D.A., Boll, B. and Diehl, V. (2014). Pharmacotherapy of Hodgkin lymphoma: standard
approaches and future perspectives. Expert opinion on pharmacotherapy 15,8:1139-1151.
Eichenauer, D.A. and Engert, A. (2014). Antibodies and antibody-drug conjugates in the treatment of
Hodgkin lymphoma. European journal of haematology 93,1:1-8.
Evens, A.M., Carson, K.R., Kolesar, J., et al. (2014). A multicenter phase II study incorporating highdose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's
lymphoma. Annals of Oncology 25,7:1449.
Feldman, T., Mato, A.R., Chow, K.F., et al. (2014). Addition of lenalidomide to rituximab, ifosfamide,
carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
British journal of haematology 166,1:77-83.
Ferreri, A.J., Ciceri, F., Brandes, A.A., et al. (2014). MATILDE chemotherapy regimen for primary CNS
lymphoma: results at a median follow-up of 12 years. Neurology 82,15:1370-1373.
3
4
Flinn, I.W., Kahl, B.S., Leonard, J.P., et al. (2014). Idelalisib, a selective inhibitor of
phosphatidylinositol 3-kinase-, as therapy for previously treated indolent non-Hodgkin lymphoma.
Blood 123,22:3406-3413.
Flinn, I.W., van der Jagt, R., Kahl, B.S., et al. (2014). Randomized trial of bendamustine-rituximab or
R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood
123,19:2944-2952.
Ganjoo, K., Hong, F., Horning, S.J., et al. (2014). Bevacizumab and cyclosphosphamide, doxorubicin,
vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell
neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & lymphoma
55,4:768-772.
Hertzberg, M., Matthews, J.P., Stone, J.M., et al. (2014). A phase III randomized trial of high-dose
CEOP+filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year
follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. American
Journal of Hematology 89,5:536-541.
Kolstad, A., Laurell, A., Jerkeman, M., et al. (2014). Nordic MCL3 study: 90Y-ibritumomab-tiuxetan
added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood
123,19:2953-2959.
Levy, R., Ganjoo, K.N., Leonard, J.P., et al. (2014). Active idiotypic vaccination versus control
immunotherapy for follicular lymphoma. Journal of Clinical Oncology 32,17:1797-1803.
Nabhan, C., Ollberding, N.J., Villines, D., et al. (2014). A systematic review of comparative schedulerelated toxicities with maintenance rituximab in follicular and mantle cell lymphomas. Leukemia &
lymphoma 55,6:1288-1294.
Ogura, M., Ando, K., Suzuki, T., et al. (2014). A multicentre phase II study of vorinostat in patients
with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
British journal of haematology 165,6:768-776.
Ogura, M., Ishida, T., Hatake, K., et al. (2014). Multicenter phase II study of mogamulizumab (KW0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral
T-cell lymphoma and cutaneous T-cell lymphoma. Journal of Clinical Oncology 32,11:1157-1163.
Ozkan, H.A., Bal, C. and Gulbas, Z. (2014). Chemomobilization with high-dose etoposide and G-CSF
results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report
from a single institution study and review. European journal of haematology 92,5:390-397.
Palanca-Wessels, M.C. and Press, O.W. (2014). Advances in the treatment of hematologic
malignancies using immunoconjugates. Blood 123,15:2293-2301.
Rizzieri DA. Johnson JL. Byrd JC. Lozanski G. Blum KA. Powell BL. Shea TC. Nattam S. Hoke E. Cheson
BD. Larson RA. Alliance for Clinical Trials In Oncology (ACTION). (2014). Improved efficacy using
rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or
aggressive lymphomas: cancer and Leukemia Group B study 10 002. British journal of haematology
165,1:102-111.
Robak, T. and Robak, E. (2014). Current Phase II antibody-drug conjugates for the treatment of
lymphoid malignancies. Expert opinion on investigational drugs 23,7:911-924.
4
5
Ruan, J., Gregory, S.A., Christos, P., et al. (2014). Long-term follow-up of R-CHOP with bevacizumab
as initial therapy for mantle cell lymphoma: clinical and correlative results. Clinical lymphoma,
myeloma & leukemia 14,2:107-113.
Russo, F., Corazzelli, G., Frigeri, F., et al. (2014). A phase II study of dose-dense and dose-intense
ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin
lymphoma. British journal of haematology 166,1:118-129.
Salar, A., Avivi, I., Bittner, B., et al. (2014). Comparison of Subcutaneous Versus Intravenous
Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a
Two-Stage, Phase IB Study. Journal of Clinical Oncology 32,17:1782-1791.
Sanchez Ruiz, A.C., de la Cruz-Merino, L. and Provencio Pulla, M. (2014). Role of consolidation with
yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma. Therapeutic
Advances in Hematology 5,3:78-90.
Sotomayor, E.M., Young, K.H. and Younes, A. (2014). Clinical roundtable monograph: CD30 in
lymphoma: its role in biology, diagnostic testing, and targeted therapy. Clinical Advances in
Hematology & Oncology 12,4 Suppl 10:1-22.
Wang, M., Popplewell, L.L., Collins, R.H.,Jr, et al. (2014). Everolimus for patients with mantle cell
lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. British
journal of haematology 165,4:510-518.
Pathology, Staging, Polymorphisms & Biomarkers
Cook, J.R., Goldman, B., Tubbs, R.R., et al. (2014). Clinical significance of MYC expression and/or
"high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704
correlative study. American Journal of Surgical Pathology 38,4:494-501.
Dunleavy, K. and Wilson, W.H. (2014). Appropriate management of molecular subtypes of diffuse
large B-cell lymphoma. Oncology (Williston Park) 28,4:326-334.
Ferreira, A.C., Robaina, M.C., Rezende, L.M., et al. (2014). Histone deacetylase inhibitor prevents cell
growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR143, miR-145, and miR-101. Annals of Hematology 93,6:983-993.
Gasparini, C., Celeghini, C., Monasta, L., et al. (2014). NF-B pathways in hematological malignancies.
Cellular & Molecular Life Sciences 71,11:2083-2102.
Giannini, C., Dogan, A. and Salomao, D.R. (2014). CNS lymphoma: a practical diagnostic approach.
Journal of Neuropathology & Experimental Neurology 73,6:478-494.
Hales, E.C., Taub, J.W. and Matherly, L.H. (2014). New insights into Notch1 regulation of the PI3KAKT-mTOR1 signaling axis: targeted therapy of -secretase inhibitor resistant T-cell acute
lymphoblastic leukemia. Cellular signalling 26,1:149-161.
Hatzi, K. and Melnick, A. (2014). Breaking bad in the germinal center: how deregulation of BCL6
contributes to lymphomagenesis. Trends in molecular medicine 20,6:343-352.
5
6
He, X., Chen, Z., Fu, T., et al. (2014). Ki-67 is a valuable prognostic predictor of lymphoma but its
utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer
14,153.
Hsi, E.D., Said, J., Macon, W.R., et al. (2014). Diagnostic accuracy of a defined immunophenotypic
and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL
study group project. American Journal of Surgical Pathology 38,6:768-775.
Lossos, C., Bayraktar, S., Weinzierl, E., et al. (2014). LMO2 and BCL6 are associated with improved
survival in primary central nervous system lymphoma. British journal of haematology 165,5:640-648.
Sakata-Yanagimoto, M., Enami, T., Yokoyama, Y., et al. (2014). Disease-specific mutations in mature
lymphoid neoplasms: recent advances. Cancer Science 105,6:623-629.
Shaw, A., Iyer, V., Rooney, N., et al. (2014). Diagnosis of primary cerebral lymphomas: possible
value of PCR testing in equivocal cases requiring rebiopsy. British journal of neurosurgery 28,2:214219.
Sovani, V., Harvey, C., Haynes, A.P., et al. (2014). Bone marrow trephine biopsy involvement by
lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic
biopsy, aspirate and peripheral blood findings. Journal of clinical pathology 67,5:389-395.
Zhou, C., Cui, S., Zhou, R., et al. (2014). Association between interleukin-4 -590C > T polymorphism
and non-Hodgkin's lymphoma risk. Tumour Biology 35,4:3041-3045.
Prognosis, Survival & Risk Factors
Cella, L., Liuzzi, R., D'Avino, V., et al. (2014). Pulmonary damage in Hodgkin's lymphoma patients
treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury. Acta
Oncologica 53,5:613-619.
Cohen, J.B., Geyer, S.M., Lozanski, G., et al. (2014). Complete response to induction therapy in
patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged
progression-free survival. Cancer 120,11:1677-1685.
Daniels, L.A., Krol, A.D., de Graaf, M.A., et al. (2014). Screening for coronary artery disease after
mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and
acceptance+. Annals of Oncology 25,6:1198-1203.
Guitart, J., Deonizio, J., Bloom, T., et al. (2014). High incidence of gastrointestinal tract disorders and
autoimmunity in primary cutaneous marginal zone B-cell lymphomas. JAMA Dermatology
150,4:412-418.
Gurney, J.G., Kaste, S.C., Liu, W., et al. (2014). Bone mineral density among long-term survivors of
childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study. Pediatric
Blood & Cancer 61,7:1270-1276.
6
7
Hoster, E., Klapper, W., Hermine, O., et al. (2014). Confirmation of the mantle-cell lymphoma
International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma
Network. Journal of Clinical Oncology 32,13:1338-1346.
Jochem, C., Leitzmann, M.F., Keimling, M., et al. (2014). Physical activity in relation to risk of
hematologic cancers: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers &
Prevention 23,5:833-846.
Maurer, M.J., Ghesquieres, H., Jais, J.P., et al. (2014). Event-free survival at 24 months is a robust
end point for disease-related outcome in diffuse large B-cell lymphoma treated with
immunochemotherapy. Journal of Clinical Oncology 32,10:1066-1073.
Radiotherapy & Imaging
Adams, H.J., Kwee, T.C., de Keizer, B., et al. (2014). Systematic review and meta-analysis on the
diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly
diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?. Annals of Oncology
25,5:921-927.
El-Galaly, T.C., Mylam, K.J., Bogsted, M., et al. (2014). Role of routine imaging in detecting recurrent
lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin
lymphoma. American Journal of Hematology 89,6:575-580.
Gallamini, A., Barrington, S.F., Biggi, A., et al. (2014). The predictive role of interim positron emission
tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation
criteria of the Deauville five-point scale. Haematologica 99,6:1107-1113.
Gallamini, A. and Borra, A. (2014). Role of PET in Lymphoma. Current Treatment Options in Oncology
15,2:248-261.
Illidge, T., Specht, L., Yahalom, J., et al. (2014). Modern radiation therapy for nodal non-Hodgkin
lymphoma-target definition and dose guidelines from the International Lymphoma Radiation
Oncology Group. International journal of radiation oncology, biology, physics 89,1:49-58.
Kobe, C., Kuhnert, G., Kahraman, D., et al. (2014). Assessment of tumor size reduction improves
outcome prediction of positron emission tomography/computed tomography after chemotherapy
in advanced-stage hodgkin lymphoma. Journal of Clinical Oncology 32,17:1776-1781.
Kostakoglu, L. and Cheson, B.D. (2014). Current role of FDG PET/CT in lymphoma. European Journal
of Nuclear Medicine & Molecular Imaging 41,5:1004-1027.
Martelli, M., Ceriani, L., Zucca, E., et al. (2014). [18F]Fluorodeoxyglucose Positron Emission
Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell
Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study.
Journal of Clinical Oncology 32,17:1769-1775.
Oki, Y., Chuang, H., Chasen, B., et al. (2014). The prognostic value of interim positron emission
tomography scan in patients with classical Hodgkin lymphoma. British journal of haematology
165,1:112-116.
7
8
Picardi, M., Pugliese, N., Cirillo, M., et al. (2014). Advanced-stage Hodgkin Lymphoma: US/Chest
Radiography for Detection of Relapse in Patients in First Complete Remission-A Randomized Trial
of Routine Surveillance Imaging Procedures. Radiology 272,1:262-274.
Raemaekers, J.M., Andre, M.P., Federico, M., et al. (2014). Omitting radiotherapy in early positron
emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk
of early relapse: Clinical results of the preplanned interim analysis of the randomized
EORTC/LYSA/FIL H10 trial. Journal of Clinical Oncology 32,12:1188-1194.
Weiler-Sagie, M., Kagna, O., Dann, E.J., et al. (2014). Characterizing bone marrow involvement in
Hodgkin's lymphoma by FDG-PET/CT. European Journal of Nuclear Medicine & Molecular Imaging
41,6:1133-1140.
Yahalom, J. (2014). Radiotherapy of follicular lymphoma: updated role and new rules. Current
Treatment Options in Oncology 15,2:262-268
Zacher, J., Kasenda, B., Engert, A., et al. (2014). The role of additional radiotherapy for primary
central nervous system lymphoma. Cochrane Database of Systematic Reviewsz 6,009211.
Special Populations
Held, G., Murawski, N., Ziepert, M., et al. (2014). Role of radiotherapy to bulky disease in elderly
patients with aggressive B-cell lymphoma. Journal of Clinical Oncology 32,11:1112-1118.
Huynh-Le, M.P., Walker, A.J., Kominers, S.D., et al. (2014). Patterns of failure after involved field
radiation therapy for pediatric and young adult Hodgkin lymphoma. Pediatric Blood & Cancer
61,7:1210-1214.
Percival, M.E., Hoppe, R.T. and Advani, R.H. (2014). Bulky mediastinal classical Hodgkin lymphoma
in young women. Oncology (Williston Park) 28,3:253-256.
Place, A.E., Frederick, N.N. and Sallan, S.E. (2014). Therapeutic approaches to haematological
malignancies in adolescents and young adults. British journal of haematology 164,1:3-14.
Samochatova, E.V., Maschan, A.A., Shelikhova, L.N., et al. (2014). Therapy of Advanced-stage Mature
B-cell Lymphoma and Leukemia in Children and Adolescents With Rituximab and Reduced
Intensity Induction Chemotherapy (B-NHL 2004M Protocol): The Results of a Multicenter Study.
Journal of Pediatric Hematology/Oncology 36,5:395-401.
Terezakis, S.A., Metzger, M.L., Hodgson, D.C., et al. (2014). ACR Appropriateness Criteria Pediatric
Hodgkin Lymphoma. Pediatric Blood & Cancer 61,7:1305-1312.
Vitolo, U., Chiappella, A., Franceschetti, S., et al. (2014). Lenalidomide plus R-CHOP21 in elderly
patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label,
multicentre, phase 2 trial. Lancet Oncology 15,7:730-737.
8
9
Supportive Care & Symptom Management
Felbel, S., Meerpohl, J.J., Monsef, I., et al. (2014). Yoga in addition to standard care for patients with
haematological malignancies. Cochrane Database of Systematic Reviews 6,010146.
Langeberg, W.J., Siozon, C.C., Page, J.H., et al. (2014). Use of pegfilgrastim primary prophylaxis and
risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or nonHodgkin's lymphoma. Supportive Care in Cancer 22,8:2167-2175.
Lee, S.Y., Kurita, N., Yokoyama, Y., et al. (2014). Glucocorticoid-induced diabetes mellitus in
patients with lymphoma treated with CHOP chemotherapy. Supportive Care in Cancer 22,5:13851390.
Morrison, V.A. (2014). Infections in patients with leukemia and lymphoma. Cancer Treatment &
Research 161,319-349.
Transplantation
Harrison, S.J., Hsu, A.K., Neeson, P., et al. (2014). Early thymus and activation-regulated chemokine
(TARC) reduction and response following panobinostat treatment in patients with
relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leukemia &
lymphoma 55,5:1053-1060.
Kharfan-Dabaja, M.A., Hamadani, M., Sibai, H., et al. (2014). Managing Hodgkin lymphoma relapsing
after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone marrow
transplantation 49,5:599-606.
Kim, J.H., Stein, A., Tsai, N., et al. (2014). Extramedullary relapse following total marrow and
lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
International journal of radiation oncology, biology, physics 89,1:75-81.
Sureda, A., Domenech, E., Schmitz, N., et al. (2014). The Role of Allogeneic Stem Cell
Transplantation in Hodgkin's Lymphoma. Current Treatment Options in Oncology 15,2:238-247.
Please note that the journal articles you are accessing are subject to the terms and conditions imposed
by the publisher, so there will be a limit on the number of articles an individual may download or print from
a single issue of a journal. You can consult your local NHSGGC library with any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin:
OVID databases
9